Belite Bio, Inc
183.16USD
-9.6900 (-5.02%)
Consensus EPS on the street’s adjusted basis, not the filed GAAP figure — which is why the actuals here can differ from the income statement.
| Period | Consensus EPS | 90 days ago | Revisions up (30d) | Revisions down (30d) |
|---|---|---|---|---|
| Current quarter | $-0.77▲ | $-0.82 | 4 | 1 |
| Next quarter | $-0.9▲ | $-0.94 | 3 | 2 |
| Current year | $-2.94▲ | $-3.28 | 3 | 1 |
| Next year | $1.92▲ | $0.94 | 1 | 0 |
Beat in 1 of the last 4
| Quarter | Estimate | Actual | Surprise |
|---|---|---|---|
| 2026-06-30 | $-0.78 | $-0.7 | +0.08 (+9.9%) |
| 2026-03-31 | $-0.64 | $-0.68 | -0.04 (-5.8%) |
| 2025-12-31 | $-0.54 | $-0.7 | -0.16 (-30.3%) |
| 2025-09-30 | $-0.49 | $-0.65 | -0.16 (-32.7%) |
58 ratings from 9 firms
Ratings are attributed to the research firm, not to individual analysts. See every ticker.
| Firm | Action | Rating | Price Target | Date |
|---|---|---|---|---|
| HC Wainwright & Co. | Maintained | Buy | $214 $245 | Sep 8, 2026 |
| Canaccord Genuity | Initiated | Buy | $303 | Sep 4, 2026 |
| Morgan Stanley | Maintained | Overweight | $201 $206 | Aug 14, 2026 |
| Cantor Fitzgerald | Maintained | Overweight | $266 $270 | Aug 14, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $200 $214 | Aug 12, 2026 |
| HC Wainwright & Co. | Reiterated | Buy | $200 | Jun 15, 2026 |
| Mizuho | Maintained | Outperform | $223 $215 | May 26, 2026 |
| HC Wainwright & Co. | Reiterated | Buy | $200 | May 21, 2026 |
| HC Wainwright & Co. | Reiterated | Buy | $200 | Apr 22, 2026 |
| HC Wainwright & Co. | Reiterated | Buy | $200 | Apr 13, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $185 $200 | Mar 3, 2026 |
| Morgan Stanley | Maintained | Overweight | $191 $201 | Mar 3, 2026 |
| Cantor Fitzgerald | Maintained | Overweight | $200 $266 | Mar 3, 2026 |
| HC Wainwright & Co. | Reiterated | Buy | $185 | Jan 28, 2026 |
| B of A Securities | Initiated | Buy | $195 | Jan 26, 2026 |
| Morgan Stanley | Initiated | Overweight | $191 | Jan 6, 2026 |
| Mizuho | Upgraded from Neutral | Outperform | $105 $194 | Dec 2, 2025 |
| HC Wainwright & Co. | Maintained | Buy | $98 $185 | Dec 1, 2025 |
| Mizuho | Initiated | Neutral | $105 | Nov 20, 2025 |
| Benchmark | Maintained | Buy | $80 $132 | Oct 31, 2025 |
| HC Wainwright & Co. | Maintained | Buy | $100 $98 | Sep 15, 2025 |
| HC Wainwright & Co. | Reiterated | Buy | $100 | Jul 3, 2025 |
| Cantor Fitzgerald | Reiterated | Overweight | — | May 15, 2025 |
| HC Wainwright & Co. | Reiterated | Buy | $100 | May 15, 2025 |
| Benchmark | Reiterated | Buy | $80 | Mar 26, 2025 |
62 filings from 7 insiders · 0 buy / 0 sell over 6m
Officers and directors of BLTE, from the last two years of filings. Grants, gifts and option exercises are shown but not colour-coded — they are compensation, not a view on the price.
| Insider | Action | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Lin Yu-HsinDirector; Officer, Chief Executive Officer | Sell | 2.7k | $198.09 | $535k | Sep 8, 2026 |
| Lin Yu-HsinDirector; Officer, Chief Executive Officer | Sell | 8.8k | $197.36 | $1.73M | Sep 8, 2026 |
| Lin Yu-HsinDirector; Officer, Chief Executive Officer | Sell | 6.1k | $196.54 | $1.19M | Sep 8, 2026 |
| Lin Yu-HsinDirector; Officer, Chief Executive Officer | Sell | 6.1k | $195.62 | $1.19M | Sep 8, 2026 |
| Lin Yu-HsinDirector; Officer, Chief Executive Officer | Sell | 2.4k | $194.33 | $466k | Sep 8, 2026 |
| Chuang Hao-YuanDirector; Officer, Chief Financial Officer | Sell | 2.6k | $198.05 | $507k | Sep 8, 2026 |
| Chuang Hao-YuanDirector; Officer, Chief Financial Officer | Sell | 4.6k | $197.23 | $908k | Sep 8, 2026 |
| Chuang Hao-YuanDirector; Officer, Chief Financial Officer | Sell | 4.5k | $196.47 | $879k | Sep 8, 2026 |
| Chuang Hao-YuanDirector; Officer, Chief Financial Officer | Sell | 4.1k | $195.60 | $806k | Sep 8, 2026 |
| Chuang Hao-YuanDirector; Officer, Chief Financial Officer | Sell | 2.2k | $194.28 | $427k | Sep 8, 2026 |
| Lin Yu-HsinDirector; Officer, Chief Executive Officer | Sell | 8.1k | $193.13 | $1.57M | Sep 4, 2026 |
| Lin Yu-HsinDirector; Officer, Chief Executive Officer | Sell | 4.2k | $192.54 | $810k | Sep 4, 2026 |
| Lin Yu-HsinDirector; Officer, Chief Executive Officer | Sell | 11.1k | $191.15 | $2.12M | Sep 4, 2026 |
| Lin Yu-HsinDirector; Officer, Chief Executive Officer | Sell | 600 | $190.39 | $114k | Sep 4, 2026 |
| Lin Yu-HsinDirector; Officer, Chief Executive Officer | Sell | 9.0k | $189.34 | $1.70M | Sep 4, 2026 |
| Lin Yu-HsinDirector; Officer, Chief Executive Officer | Sell | 3.0k | $188.26 | $573k | Sep 4, 2026 |
| Lin Yu-HsinDirector; Officer, Chief Executive Officer | Sell | 6.2k | $187.25 | $1.16M | Sep 4, 2026 |
| Lin Yu-HsinDirector; Officer, Chief Executive Officer | Sell | 7.8k | $186.32 | $1.45M | Sep 4, 2026 |
| Lin Yu-HsinDirector; Officer, Chief Executive Officer | Sell | 4.6k | $185.34 | $851k | Sep 4, 2026 |
| Lin Yu-HsinDirector; Officer, Chief Executive Officer | Sell | 6.3k | $184.52 | $1.15M | Sep 4, 2026 |
No analyst notes on BLTE yet.
Analyst Ratings
9 analysts covering
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Consensus |
|---|---|---|---|---|---|---|
| Current | 2 | 7 | 0 | 0 | 0 | Buy1.78 |
| 1 mo ago | 2 | 6 | 0 | 0 | 0 | Buy1.75 |
| 2 mo ago | 2 | 6 | 0 | 0 | 0 | Buy1.75 |
| 3 mo ago | 2 | 6 | 0 | 0 | 0 | Buy1.75 |